CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
MyoGene Bio
Company Type: Therapeutic development
Main focus: Developing novel therapeutics for muscle diseases
Company stage: Pre-clinical
Diseases: Duchenne muscular dystrophy and other muscular diseases
Genome-editing tool: CRISPR-Cas9
Funding stage: Unknown.
Location: San Diego, California, USA
Website: http://www.myogenebio.com/x4555.html
Pipeline:
Partners:
MyoGene Bio is a biotechnology company specialising in the development of genetic therapies for muscle diseases such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy. Their main focus, MyoDys45-55, surrounds the development of a novel CRISPR-Cas9 gene-editing platform to treat DMD. MyoDys45-55 is currently at pre-clinical stage and has demonstrated efficient restoration of the dystrophin protein in mice and human stem cells.
